

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
				Application Number	10/561,874
				Filing Date	April 25, 2007
				First Named Inventor	Dirk Seegert
				Art Unit	1646
				Examiner Name	Prema Maria Mertz
Sheet	1	Of	4	Attorney Docket Number	31304-763.831

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2008/0227155 A1	09/18/2008	Seegert et al.	

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	2.	ATREYA, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000 May;6(5):583-8.			T <sup>6</sup>
	3.	BITTER, et al. Expression and Secretion Vectors for Yeast. Methods in Enzymology. 1987;153: 516-544.			
	4.	BROGLIE, et al. Light-regulated expression of a pea ribulose-1,5-bisphosphate carboxylase small subunit gene in transformed plant cells. Science. 1984 May 25;224(4651):838-43.			
	5.	COLBERE-GARAPIN, et al. A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol. 1981 Jul 25;150(1):1-14.			
	6.	CORUZZI, et al. Tissue-specific and light-regulated expression of a pea nuclear gene encoding the small subunit of ribulose-1,5-bisphosphate carboxylase. EMBO J. 1984 Aug;3(8):1671-9.			
	7.	CUNNINGHAM, et al. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science. 1989 Jun 2;244(4908):1081-5.			
	8.	CUNNINGHAM, et al. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science. 1989 Mar 10;243(4896):1330-6.			
	9.	ENGELHARD, et al. The insect tracheal system: a conduit for the systemic spread of <i>Autographa californica</i> M nuclear polyhedrosis virus. Proc Natl Acad Sci U S A. 1994 April 12; 91(8): 3224-3227.			
	10.	FINGL, et al. Chapter 1, General Principles, The Pharmacological Basis of Therapeutics, Goodman and Gilman, eds. Macmillan Publishing Co., New York, pp. 1			

Examiner Signature	/Prema Mertz/	Date Considered	12/07/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/561,874
Sheet	2	Of	4	Filing Date	April 25, 2007
				First Named Inventor	Dirk Seegert
				Art Unit	1646
				Examiner Name	Prema Maria Mertz
				Attorney Docket Number	31304-763.831

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		46 (1975)	
	11.	GOODSON, et al. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (N Y). 1990 Apr;8(4):343-6.	
	12.	GRACE, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res. 2001 Dec;21(12):1103-15.	
	13.	HARTMAN, et al. Two dominant-acting selectable markers for gene transfer studies in mammalian cells. Proc Natl Acad Sci U S A. 1988 Nov;85(21):8047-51.	
	14.	KATRE, N. V. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immunol. 1990 Jan 1;144(1):209-13.	
	15.	KRAUSE, et al. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol. 2002 Dec 1;169(11):6610-6.	
	16.	LEVY, et al. What does Stat3 do? J Clin Invest. 2002 May 1; 109(9): 1143-1148.	
	17.	LOGAN, et al. Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3655-9.	
	18.	LOWY, et al. Isolation of transforming DNA: cloning the hamster apt gene. Cell. 1980 Dec;22(3):817-23.	
	19.	MÜLLBERG, et al. IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol. 2000 May 1;164(9):4672-7.	
	20.	MURRY, L.E., Agrobacterium-Mediated plant transformation in McGraw Hill Yearbook of Science and Technology. McGraw Hill, New York, NY. 1992; 191-196.	
	21.	NISHIMOTO, T. A new role of ran GTPase. Biochem Biophys Res Commun. 1999 Sep 7;262(3):571-4.	
	22.	NISHIMOTO, et al. Anticytokine therapy in autoimmune diseases. Intern. Med. 1999 Feb; 38(2): 178-82	
	23.	PEPINSKY, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther. 2001 Jun;297(3):1059-66.	

Examiner Signature	/Prema Mertz/	Date Considered	12/07/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i></p>				<b>Complete if Known</b>			
				Application Number		10/561,874	
				Filing Date		April 25, 2007	
				First Named Inventor		Dirk Seegert	
				Art Unit		1646	
				Examiner Name		Prema Maria Mertz	
Sheet	3	Of	4	Attorney Docket Number	31304-763.831		

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	24.	PETTIT, et al. Structure-function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation, and homology modeling. <i>J Biol Chem.</i> 1997 Jan 24;272(4):2312-8.		T <sup>6</sup>
	25.	RAKEMANN, et al. The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. <i>J Biol Chem.</i> 1999 Jan 15;274(3):1257-66.		
	26.	RHODES, et al. Identification of MRF4: a new member of the muscle regulatory factor gene family. <i>Genes Dev.</i> 1989 Dec;3(12B):2050-61.		
	27.	RHODES, et al. Transformation of Maize by Electroporation of Embryos. (1995) <i>Methods Mol. Biol.</i> 55: 121-131		
	28.	SAMBROOK, J. <i>Molecular Cloning: A Laboratory Manual.</i> Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY(1989). (Cover pages and table of contents pages only)		
	29.	SCHARF, et al. Heat stress promoters and transcription factors. <i>Results Probl Cell Differ.</i> 1994;20:125-62.		
	30.	SUZUKI, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. <i>J Exp Med.</i> 2001 Feb 19;193(4):471-81.		
	31.	TAKAMATSU, et al. Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TMV-RNA. <i>EMBO J.</i> 1987 Feb;6(2):307-11.		
	32.	TANG, et al. Studies on the PEGylation of Protein at a Specific Site: Sulphydryl-PEGylation of 97Cys-IFN-gamma. <i>Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai).</i> 1996;28(3):312-315.		
	33.	TURKSON, et al. STAT proteins: novel molecular targets for cancer drug discovery. <i>Oncogene.</i> 2000 Dec 27;19(56):6613-26.		
	34.	WIGLER, et al. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. <i>Cell.</i> 1977 May;11(1):223-32.		
	35.	WIGLER, et al. Transformation of mammalian cells with an amplifiable dominant-acting gene. <i>Proc Natl Acad Sci U S A.</i> 1980 Jun;77(6):3567-70.		

Examiner Signature	/Prema Mertz/	Date Considered	12/07/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				<b>Complete if Known</b>	
Substitute for form 1449/PTO				Application Number	10/561,874
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Filing Date	April 25, 2007
				First Named Inventor	Dirk Seegert
				Art Unit	1646
				Examiner Name	Prema Maria Mertz
Sheet	4	Of	4	Attorney Docket Number	31304-763.831

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	36.	WINTER, et al. The expression of heat shock protein and cognate genes during plant development. Results Probl Cell Differ. 1991;17:85-105.	
	37.	YOSHIZAKI, et al. Interleukin-6 in autoimmune disorders. Semin Immunol. 1992 Jun;4(3):155-66.	
	38.	YOUNGSTER, et al. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des. 2002;8(24):2139-57.	

Examiner Signature	/Prema Mertz/	Date Considered	12/07/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.